BioLargo, Inc. reported a significant decline in financial performance for the fiscal year ending December 31, 2025, with total revenues of $7.77 million, a 56% decrease from $17.78 million in 2024. The company attributed this drop primarily to a substantial reduction in sales from its largest private-label customer, Pooph Inc., which ceased purchasing products and defaulted on payments. This led to a net loss of $15.19 million, compared to a loss of $4.35 million in the previous year, marking a 249% increase in net losses year-over-year. The company also recorded a credit loss expense of $3.89 million related to the Pooph litigation, which further impacted its financial results.
In terms of operational developments, BioLargo's subsidiary ONM Environmental, which focuses on odor and VOC control products, saw revenues plummet by 62% to $5.91 million. Conversely, the engineering division, BioLargo Engineering, Science & Technologies (BLEST), experienced a 96% increase in service revenues, reaching $1.99 million, driven by additional engineering consulting contracts. Despite this growth, BLEST still reported an operating loss of $1.09 million, reflecting ongoing investments in internal projects, including the development of the Aqueous Electrostatic Concentrator (AEC) for PFAS removal.
The company has been actively pursuing strategic developments, including the commercialization of its technologies. BioLargo's Clyra Medical Technologies, which focuses on medical products, did not generate revenue in 2025 but received its first purchase order for its ViaCLYR product in February 2026. The subsidiary has raised $5.75 million in debt and equity to support its operations and product development. Additionally, BioLargo Energy Technologies (BETI) continues to develop its Cellinity battery technology, although it has not yet generated revenue.
As of March 2, 2026, BioLargo employed 46 individuals, with plans to expand its workforce to meet growing operational demands. The company is also exploring new partnerships to enhance its market reach, particularly in the water treatment sector, where it aims to leverage its innovative AEC technology. However, the company faces significant challenges, including the need for additional financing to sustain operations and the ongoing litigation with Pooph, which could impact future revenue streams. BioLargo's management remains optimistic about the potential for its technologies but acknowledges the need for continued capital investment to achieve profitability.
About BIOLARGO, INC.
BioLargo, Inc. develops and commercializes innovative cleantech solutions addressing environmental and health challenges. Its core businesses include industrial and consumer odor and VOC control products, advanced water treatment systems targeting contaminants like PFAS and micropollutants, long-duration battery energy storage technologies, and antimicrobial medical devices. Operating through specialized subsidiaries, BioLargo serves municipal, industrial, and healthcare markets by delivering patented, energy-efficient, and environmentally sustainable technologies supported by engineering services.
About 10-K Filings
A 10-K form is a comprehensive annual report that public companies in the United States must file with the SEC, providing a detailed overview of the company's financial condition, performance, and business strategies.
Key points about the 10-K:
- Frequency: Filed annually, typically within 60 to 90 days after the end of the company's fiscal year.
-
Content: It includes:
- Detailed financial statements audited by an independent accounting firm
- Management's Discussion and Analysis (MD&A) of financial condition and results
- Description of the company's business, properties, and legal proceedings
- Risk factors and market risks
- Executive compensation and corporate governance information
- Importance: Considered the most comprehensive and important document a public company files with the SEC.
- Length: Often exceeds 100 pages due to its extensive and detailed nature.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.